Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...
18h
Hosted on MSNNovavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi PartnershipNovavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.
Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
9d
GlobalData on MSNSanofi moves closer to selling controlling stake in $17bn-valued OpellaSanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...
Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results